Welcome to our dedicated page for Marker Therapeut news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeut stock.
Marker Therapeutics, Inc. reports developments as a clinical-stage immuno-oncology company developing non-genetically modified Multi-Antigen Recognizing T cell therapies for hematologic malignancies and solid tumor indications. Its recurring company updates center on the MAR-T cell platform, MT-601 in lymphoma, MT-401-OTS as an off-the-shelf program, and pancreatic cancer research connected to technology developed at Baylor College of Medicine.
Company news also covers clinical observations from named studies, non-dilutive funding from government and cancer-research programs, scientific publications and medical-meeting presentations, quarterly financial results, conference participation, shareholder voting matters, and board governance changes.
Marker Therapeutics (MRKR), a clinical-stage immuno-oncology company, announced its participation in the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium. Juan Vera, M.D., President and CEO, will present on December 12, 2024, at 1:30 PM EST.
The presentation will showcase Marker's technology and clinical developments in T cell-based immunotherapies for treating hematological malignancies and solid tumor indications. Registered participants can access the presentation through the event portal, and a replay will be available on the Company's IR website under Events & Presentations.
Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced its participation in the upcoming Citizens JMP Hematology and Oncology Summit on December 2, 2024. CEO Juan Vera will present the company's technology and clinical developments at 11 AM EST during this virtual event.
The presentation will showcase Marker's focus on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumor treatments. Following the presentation, a replay will be available on the company's IR website. The management team will also conduct one-on-one meetings with registered investors to discuss business and clinical development strategies.
Marker Therapeutics (MRKR) reported Q3 2024 financial results and business updates. The company received two $2 million NIH SBIR grants to support MT-601 clinical trials in lymphoma and pancreatic cancer patients. The ongoing Phase 1 APOLLO study for MT-601 in lymphoma patients shows promising activity, with preliminary data expected by year-end. Financial highlights include $9 million in cash and cash equivalents, expected to fund operations into October 2025. Q3 2024 showed R&D expenses of $3.5 million, G&A expenses of $0.9 million, and a net loss of $2.3 million.
Marker Therapeutics (Nasdaq: MRKR) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Preliminary safety and efficacy data from the Phase 1 APOLLO study of MT-601 in lymphoma patients showed objective responses in 3 out of 3 participants.
2. MT-601 was well-tolerated with no cytokine release syndrome or neurotoxicity observed.
3. Marker received a $2 million NIH SBIR grant to support MT-601 clinical investigation.
4. Q2 2024 financial results: $7.8 million in cash and cash equivalents, $2.3 million in R&D expenses, $1.1 million in G&A expenses, and a net loss of $2.2 million.
5. The company expects its cash to fund operations into Q4 2025.
Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nationwide multi-center Phase 1 APOLLO study, evaluating the safety and efficacy of MT-601, a multi-tumor associated antigen-specific T cell product.
The company has now received over $19 million in non-dilutive funding. Preliminary results from the APOLLO study show objective responses in all three study participants treated at City of Hope, with no cytokine release syndrome or immune effector cell associated neurotoxicity syndrome observed. This grant supports Marker's efforts to address the unmet medical need for patients who relapse after CD19-targeting CAR-T cell therapy.
Marker Therapeutics (Nasdaq: MRKR) reported first quarter 2024 financial results and business updates. The company highlighted continued clinical progress, noting promising results in its Phase 1 APOLLO study of MT-601 for lymphoma. Significant milestones include sustained complete responses in study participants and an official nonproprietary name 'neldaleucel' for MT-601. Financially, Marker saw a reduction in R&D and G&A expenses, narrowing its net loss to $2.4 million from $4.9 million year-over-year. Cash and cash equivalents stood at $11.3 million, expected to fund operations into Q4 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.